Relationship of expression of lncRNA TPT1-AS1 and miR-30c-5p with pathological characteristics and prognosis in colon cancer

doi:10.3877/cma.j.issn.1674-0785.2022.01.014

Abstract

Abstract:

Objective

To detect the expression of the long non-coding RNA (lncRNA) tumor protein translation regulator 1-antisense RNA1 (TPT1-AS1) and microRNA (miR)-30c-5p in colon cancer, and to analyze its relationship with pathological characteristics and prognosis.

Methods

A total of 117 patients with colon cancer who underwent radical or palliative surgery were selected from January 2015 to December 2017 at the First Affiliated Hospital of Shenzhen University. The colon cancer and adjacent tissues were surgically removed, and the expression levels of lncRNA TPT1-AS1 and miR-30c-5p in these tissues were detected by qRT-PCR. The relationship between the expression levels of lncRNA TPT1-AS1 and miR-30C-5p and the pathological features of colon cancer was analyzed, and the correlation between the expression levels of lncRNA TPT1-AS1 and miR-30C-5p in colon cancer tissues was analyzed by Pearson correlation test. Kaplan-Meier curve was used to calculate the 3-year cumulative survival rate of colon cancer patients with different lncRNA TPT1-AS1 and miR-30C-5P expression levels, and Cox regression analysis was performed to analyze the prognostic factors for colon cancer patients.

Results

The expression level of the lncRNA TPT1-AS1 was significantly higher (3.405±0.555 vs 1.766±0.096) and that of miR-30c-5p was significantly lower (0.306±0.146 vs 0.872±0.267) in colon cancer tissues than in adjacent tissues (P＜0.05). The expression level of the lncRNA TPT1-AS1 was significantly higher in colon cancer TNM stage Ⅲ-Ⅳ than in stage Ⅰ-Ⅱ (3.651±0.579 vs 3.257±0.486), in T₃-T₄ colon cancer than in T₁-T₂ (3.523±0.601 vs 3.301±0.491), and in colon cancer with lymph node metastasis than in that without (3.614±0.585 vs 3.220±0.456) (P＜0.05). The expression level of miR-30C-5P was significantly lower in colon cancer TNM stage Ⅲ-Ⅳ than that in stage Ⅰ-Ⅱ (0.251±0.126 vs 0.346±0.145), in T₃-T₄ colon cancer than in T₁-T₂ (0.270±0.119 vs 0.338±0.162), and in colon cancer with lymph node metastasis than in that without (0.255±0.125 vs 0.351±0.151) (P＜0.05). Pearson correlation analysis showed that the expression of lncRNA1 TPT1-AS1 was negatively correlated with miR-30C-5P expression in colon cancer tissues (r=-0.572, P＜0.05). Kaplan-Meier survival analysis showed that the 3-year cumulative survival rate (59.32% vs 87.93%) of the group with high lncRNA TPT1-AS1 expression was significantly lower than that of the group with low lncRNA1 TPT1-AS1 expression. The 3-year cumulative survival rate of the group with high miR-30C-5P expression (85.00% vs 61.40%) was significantly higher than that of the group with low miR-30C-5P expression (P＜0.05). Multivariate Cox regression analysis showed that TNM stage Ⅲ-Ⅳ [hazard ratio (HR)=2.387, 95% confidence interval (CI): 1.004-5.671], lymph node metastasis (HR=2.667, 95%CI: 1.021-6.969), and TPT1-AS1≥3.405 (HR=2.023, 95%CI: 1.076-3.803) were independent prognostic risk factors for colon cancer patients, while mir-30C-5p ≥0.306 (HR=0.175, 95%CI: 0.012-0.423) was an independent protective factor (P＜0.05).

Conclusion

The expression of lncRNA1 TPT1-AS1 in colon cancer tissue is significantly up-regulated, and the expression of miR-30c-5p is significantly down-regulated, both of which are associated with TNM stage, depth of invasion and lymph node metastasis, are independent prognostic factors for patients, and may become markers for prognostic evaluation of colon cancer.

Key words: Colon cancer, Long non-coding RNA, Tumor protein translation regulator 1, Antisense RNA1, MicroRNA-30c-5p

Zibing Fan, Jing Shi, Hongpeng Liu, Yusong Shi, Ying Qin. Relationship of expression of lncRNA TPT1-AS1 and miR-30c-5p with pathological characteristics and prognosis in colon cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(01): 77-83.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.01.014

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I01/77

Figures/Tables 7

References 22

1	国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南(2020,北京) [J]. 中华肿瘤杂志, 2021, 43(1): 16-38.
2	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
3	Zhang Q, Bian Y, Zhu Y, et al. Integrative analysis and validation of dysregulated long non-coding RNAs in colon cancer [J]. J Cell Mol Med, 2020, 24(4): 2610-2621.
4	Wang W, Yang F, Zhang L, et al. LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas [J]. Oncotarget, 2016, 7(47): 77225-77236.
5	Lin GB, Zhang CM, Chen XY, et al. Identification of circulating miRNAs as novel prognostic biomarkers for bladder cancer [J]. Math Biosci Eng, 2019, 17(1): 834-844.
6	Onyshchenko KV, Voitsitskyi TV, Grygorenko VM, et al. Expression of micro-RNA hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma [J]. Exp Oncol, 2020, 42(2): 115-119.
7	Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual [M]. 8th ed. New York: Springer, 2017.
8	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
9	Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(3): 145-164.
10	Wang J, Xing H, Nikzad AA, et al. Long noncoding RNA MNX1 antisense RNA 1 exerts oncogenic functions in bladder cancer by regulating miR-218-5p/RAB1A axis [J]. J Pharmacol Exp Ther, 2020, 372(3): 237-247.
11	Jiang H, Huang G, Zhao N, et al. Long non-coding RNA TPT1-AS1 promotes cell growth and metastasis in cervical cancer via acting as a sponge for miR-324-5p [J]. J Exp Clin Cancer Res, 2018, 37(1): 169.
12	杨华湘, 李世龙, 赵宗贤, 等. 长链非编码RNA肿瘤蛋白翻译控制反义RNA 1对结肠癌细胞增殖和侵袭能力的影响 [J]. 中华实验外科杂志, 2021, 38(2): 215-217.
13	学峰. 癌相关成纤维细胞通过FAK通路诱导结肠癌细胞上皮-间质转表达并促进结肠肿瘤转移 [D]. 呼和浩特: 内蒙古医科大学, 2019.
14	Tang S, Yuan X, Song J, et al. Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer[J]. Oncol Lett, 2019, 17(1): 159-164.
15	Zhang L, Ye F, Zuo Z, et al. Long noncoding RNA TPT1-AS1 promotes the progression and metastasis of colorectal cancer by upregulating the TPT1-mediated FAK and JAK-STAT3 signalling pathways [J]. Aging (Albany NY), 2021, 13(3): 3779-3797.
16	Pei B, Li T, Qian Q, et al. Downregulation of microRNA-30c-5p was responsible for cell migration and tumor metastasis via COTL1-mediated microfilament arrangement in breast cancer [J]. Gland Surg, 2020, 9(3): 747-758.
17	Zhou Y, Shi H, Du Y, et al. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis [J]. Aging (Albany NY), 2019, 11(18): 7386-7401.
18	Beilmann-Lehtonen I, Böckelman C, Mustonen H, et al. The prognostic role of tissue TLR2 and TLR4 in colorectal cancer [J]. Virchows Arch, 2020, 477(5): 705-715.
19	刘文慧, 刘修恒, 夏超锋. Toll样因子受体4诱导的增殖在结直肠癌中的影响 [J]. 中华实验外科杂志, 2019, 36(2): 225-228.
20	闫晓菲, 赵广越, 乔鋆,等. miR-30c-5p及Toll样受体4在结肠癌中的表达及意义 [J]. 中国综合临床, 2021, 37(1): 57-61.
21	皮益苑, 周爽, 简鸣, 等. LncRNA中miRNA海绵活性与肿瘤的研究进展 [J]. 中南医学科学杂志, 2019, 47(3): 230-234.
22	Gao X, Cao Y, Li J, et al. LncRNA TPT1-AS1 sponges miR-23a-5p in glioblastoma to promote cancer cell proliferation [J]. Cancer Biother Radiopharm, 2020, 36(7): 549-555.

病理特征	例数	lncRNA TPT1-AS1	miR-30c-5
性别
男	69	3.395±0.561	0.321±0.151
女	48	3.420±0.550	0.285±0.140
t值		-0.236	1.321
P值		0.814	0.189
年龄（岁）
≥60	56	3.475±0.560	0.284±0.131
＜60	61	3.341±0.546	0.327±0.158
t值		1.305	-1.595
P值		0.195	0.114
肿瘤直径（cm）
≥5	52	3.468±0.581	0.280±0.133
＜5	65	3.355±0.532	0.327±0.154
t值		1.091	-1.761
P值		0.278	0.081
分化程度
低或未分化	47	3.475±0.605	0.282±0.136
中或高分化	70	3.358±0.517	0.322±0.152
t值		1.111	-1.465
P值		0.269	0.146
TNM分期（期）
Ⅰ~Ⅱ	73	3.257±0.486	0.346±0.145
Ⅲ~Ⅳ	44	3.651±0.579	0.251±0.126
t值		-3.944	3.982
P值		＜0.001	＜0.001
浸润深度
T₁~T₂	62	3.301±0.491	0.338±0.162
T₃~T₄	55	3.523±0.601	0.270±0.119
t值		-2.205	2.577
P值		0.029	0.011
淋巴结转移
有	55	3.614±0.585	0.255±0.125
无	62	3.220±0.456	0.351±0.151
t值		4.096	-3.722
P值		＜0.001	＜0.001

病理特征	例数	lncRNA TPT1-AS1	miR-30c-5
性别
男	69	3.395±0.561	0.321±0.151
女	48	3.420±0.550	0.285±0.140
t值		-0.236	1.321
P值		0.814	0.189
年龄（岁）
≥60	56	3.475±0.560	0.284±0.131
＜60	61	3.341±0.546	0.327±0.158
t值		1.305	-1.595
P值		0.195	0.114
肿瘤直径（cm）
≥5	52	3.468±0.581	0.280±0.133
＜5	65	3.355±0.532	0.327±0.154
t值		1.091	-1.761
P值		0.278	0.081
分化程度
低或未分化	47	3.475±0.605	0.282±0.136
中或高分化	70	3.358±0.517	0.322±0.152
t值		1.111	-1.465
P值		0.269	0.146
TNM分期（期）
Ⅰ~Ⅱ	73	3.257±0.486	0.346±0.145
Ⅲ~Ⅳ	44	3.651±0.579	0.251±0.126
t值		-3.944	3.982
P值		＜0.001	＜0.001
浸润深度
T₁~T₂	62	3.301±0.491	0.338±0.162
T₃~T₄	55	3.523±0.601	0.270±0.119
t值		-2.205	2.577
P值		0.029	0.011
淋巴结转移
有	55	3.614±0.585	0.255±0.125
无	62	3.220±0.456	0.351±0.151
t值		4.096	-3.722
P值		＜0.001	＜0.001

变量	赋值
自变量
性别	男性=1，女性=0
年龄	≥60岁=1，＜60岁=0
肿瘤直径	≥5 cm为=1，＜5 cm=0
分化程度	低或未分化为=1，中或高分化=0
TNM分期	Ⅲ~Ⅳ期=1，Ⅰ~Ⅱ期=0
浸润深度	T₃~T₄=1，T₁~T₂=0
淋巴结转移	有=1，无=0
lncRNA TPT1-AS1	≥3.405=1，＜3.405=0
miR-30c-5p	≥0.306=1，＜0.306=0
因变量
预后	死亡=1，存活=0

变量	赋值
自变量
性别	男性=1，女性=0
年龄	≥60岁=1，＜60岁=0
肿瘤直径	≥5 cm为=1，＜5 cm=0
分化程度	低或未分化为=1，中或高分化=0
TNM分期	Ⅲ~Ⅳ期=1，Ⅰ~Ⅱ期=0
浸润深度	T₃~T₄=1，T₁~T₂=0
淋巴结转移	有=1，无=0
lncRNA TPT1-AS1	≥3.405=1，＜3.405=0
miR-30c-5p	≥0.306=1，＜0.306=0
因变量
预后	死亡=1，存活=0

变量	回归系数	标准误	Wald χ²值	P值	HR值	95%CI
男性	-0.064	0.370	0.030	0.863	0.938	0.454~1.939
年龄≥60岁	0.746	0.386	3.728	0.054	2.109	0.989~4.498
肿瘤直径≥5 cm	0.346	0.360	0.923	0.337	1.413	0.698~2.862
低或未分化	0.338	0.360	0.883	0.348	1.402	0.693~2.837
TNM Ⅲ~Ⅳ期	1.270	0.411	9.562	0.002	3.561	1.592~7.964
浸润深度T₃~T₄	1.051	0.385	7.461	0.006	2.860	1.346~6.080
淋巴结转移	1.452	0.456	10.148	0.001	4.272	1.748~10.438
lncRNA TPT1-AS1≥3.405	1.235	0.268	21.247	＜0.001	3.437	2.033~5.810
miR-30c-5p≥0.306	-3.282	1.336	6.035	0.014	0.038	0.003~0.515

Please choose a citation manager

Content to export